Patent SG-11201810834W-A (SG)
Title: Hepatitis b antiviral agents
Inventor: QIU YAO-LING
IPC: C07D239/20
Filed: 2017-06-08
Abstract: PUBLISHEDUNDER THE PATENT COOPERATION TREATY (PCT) WIPO I PCT () INTERNATIONAL APPLICATION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) omit VIII Hot o III OH olo mil mu Eno lII ois (10) International Publication Number WO 2017/214395 Al (51) International Patent Classification: A61K 31/519 (2006.01) C07D 487/04 (2006.01) CO7D 239/20 (2006.01) (21) International Application Number: PCT/US2017/036553 (22) International Filing Date: 08 June 2017 (08.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/348,419 10 June 2016 (10.06.2016) US 62/443,245 06 January 2017 (06.01.2017) US (71) Applicant: ENANTA PHARMACEUTICALS, INC. [US/US]; 500 Arsenal Street, Watertown, MA 02472 (US). (72) Inventors: QIU, Yao-Ling; 29 Linda Road, Andover, MA 01810 (US). CAO, Hui; 53 Hill Road, Belmont, MA 02478 (US). PENG, Xiaowen; 85 Horse Pond Road, Sudbury, MA 01776 (US). LI, Wei; 22 April Lane, Lexington, MA 02421 (US). KASS, Jorden; 29 Wilson Ave, Apt. #2, Belmont, MA 02478 (US). GAO, Xuri; 179 Allerton Road, Unit 2, Newton, MA 02461 (US). JIN, Meizhong; 64-105 Hastings St., Wellesley, MA 02481 (US). OR, Yat, Sun; 169 Fayette Street, Watertown, MA 02472 (US). (74) Agent: HARLAN, Edgar, W. et al.; Elmore Patent Law Group, P.C., 484 Groton Road, Westford, MA 01886 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 2 I (3)) (54) Title: HEPATITIS B ANTIVIRAL AGENTS W O 20 17 / 214395 Al X B (57) : The present invention discloses compounds of Formula (I), or phar- maceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepati- tis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for ad- ministration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.